Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 157.70K | 157.90K | 158.60K | 108.70K | 118.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 157.70K | 157.90K | 158.60K | 108.70K | 118.00K |
| Cost of Revenue | 80.00K | 62.80K | 53.50K | 53.40K | 63.30K |
| Gross Profit | 77.70K | 95.10K | 105.00K | 55.30K | 54.70K |
| SG&A Expenses | 144.00K | 156.10K | 324.40K | 457.10K | 538.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 224.10K | 218.90K | 377.90K | 510.50K | 601.50K |
| Operating Income | -66.40K | -61.00K | -219.30K | -401.70K | -483.60K |
| Income Before Tax | -118.50K | -449.50K | -155.60K | -450.70K | -499.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -118.50K | -449.50K | -155.60K | -450.70K | -499.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -118.50K | -449.50K | -155.60K | -450.70K | -499.20K |
| EBIT | -66.40K | -61.00K | -219.30K | -401.70K | -483.60K |
| EBITDA | -- | -- | -218.30K | -400.70K | -482.50K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 132.63M | 132.63M | 132.63M | 132.63M | 132.63M |
| Average Diluted Shares Outstanding | 132.63M | 132.63M | 132.63M | 132.63M | 132.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |